Taysha Gene Therapies

Taysha Gene Therapies

  • Founded: 2020
  • Location: Dallas, TX
  • Employee range: 50 - 200
  • Clinical stage: Clin1/Clin2
  • Therapy area: Giant axonal neuropathy
  • Drug types: GEN, NEU, PED
  • Lead product: TSHA-120
  • Product link: https://tayshagtx.com/pipeline/
  • Funding: $150M stock Aug 2023; $181M IPO Sep 2020; $95M B Aug 2020; $30M seed Apr 2020


tayshagtx.com

linkedin.com

job board


Short description:

Adeno-associated virus gene therapies

Drug notes:

TSHA-118 Clin1/Clin2 CLN1 disease; TSHA-102 Clin1/Clin2 Rett syndrome; TSHA-105 Clin0 genetic epilepsy

Long description:

Contact us to add description: recruit@workinbiotech.com

Jobs:

Taysha Gene Therapies
Vice President, Biometrics
Remote|43 days ago
Apply
Taysha Gene Therapies
Vice President, Biometrics
Remote|43 days ago
Taysha Gene Therapies
Executive Director, Information Technology
Remote|52 days ago


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy

Contact: recruit@workinbiotech.com